|
Mutation Information
|
Mutation Site
|
K70R |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Relevant Drug
|
bictegravir (BIC);emtricitabine (FTC);tenofovir alafenamide;thymidineanalogue (TAMs) |
|
Country
|
Australia;Europe;North America |
Literature Information
|
PubMed PMID
|
31430369
|
|
Disease
|
HIV infection/AIDS
|
|
Published Year
|
2019 |
|
Journal
|
The Journal of antimicrobial chemotherapy |
|
Title
|
Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I. |
|
Author
|
Andreatta K,Willkom M,Martin R,Chang S,Wei L,Liu H,Liu YP,Graham H,Quirk E,Martin H,White KL |
|
Evidence
|
Table 4;Pre-existing NRTI-R substitutions were observed in 16% (89/543) of BIC/FTC/TAF-treated participants; the most frequently detected substitutions were M184V/I in 10% (54/543) and thymidine analogue mutations (TAMs; M41L, D67N, K70R, L210W, T215Y/F and K219Q/N/E/R) in 8.8% (48/543).
|
|
|
HIV Mutation Detail Information